Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:219 |
Name | colon cancer |
Definition | A colorectal cancer that is located_in the colon. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colon cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01274624 | Phase I | Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Pelareorep | Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01966289 | Phase I | Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine | SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | Completed | USA | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT02041481 | Phase I | Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02448173 | Phase III | A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer | Unknown status | USA | 0 | |
NCT02508077 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | DNK | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02834052 | Phase Ib/II | Pembrolizumab + Poly ICLC | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | Completed | USA | 0 |
NCT02860780 | Phase I | Prexasertib + Ralimetinib | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | Completed | USA | DEU | 0 |
NCT02980029 | Phase I | TVB-2640 | Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer | Terminated | USA | 0 |
NCT03127098 | Phase Ib/II | ETBX-011 + Nogapendekin alfa inbakicept | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | Terminated | USA | 0 |
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT03207867 | Phase II | Spartalizumab + Taminadenant | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG | 3 |
NCT03317119 | Phase I | Trametinib + Trifluridine-tipiracil hydrochloride | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03631641 | Phase II | Nivolumab | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | Terminated | USA | 0 |
NCT03711058 | Phase Ib/II | Copanlisib + Nivolumab | Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03827967 | Phase I | PalloV-CC | Trial of PalloV-CC in Colon Cancer | Completed | USA | 0 |
NCT03829410 | Phase Ib/II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation | Completed | USA | 0 |
NCT03872947 | Phase I | Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT03919292 | Phase Ib/II | Divalproex sodium + Neratinib | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | Recruiting | USA | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04294160 | Phase I | Dabrafenib + LTT462 + Spartalizumab Dabrafenib + LTT462 + TNO155 Dabrafenib + TNO155 + Trametinib Dabrafenib + LTT462 Dabrafenib + LTT462 + LXH 254 Dabrafenib + LTT462 + Trametinib | A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | Terminated | USA | NLD | ISR | GBR | ESP | DEU | CAN | BEL | AUS | 1 |
NCT04486378 | Phase II | Autogene cevumeran | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Recruiting | USA | SWE | GBR | ESP | DEU | BEL | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
NCT04799431 | Phase I | Neoantigen peptide vaccine + Poly ICLC + Retifanlimab | Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | Withdrawn | 0 | |
NCT05456165 | Phase II | Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer | Terminated | USA | 0 |
NCT05694715 | Phase I | Irinotecan + Niraparib | Combination Therapy in Cancers With Mutations in DNA Repair Genes | Recruiting | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05806931 | Phase II | Bevacizumab + Irinotecan + Oxaliplatin + Trifluridine-tipiracil hydrochloride | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer (SCOTI) | Recruiting | USA | 0 |
NCT05831995 | Phase I | ABM-168 | Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | Recruiting | USA | 0 |
NCT06130826 | Phase I | M5A-IL2 | Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT06411691 | Phase I | Balstilimab + Botensilimab + Poly ICLC + Pooled Mutant KRAS-Targeted Long Peptide Vaccine | KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | Recruiting | USA | 0 |
NCT06597721 | Phase I | AMT-754 | AMT-754 in Patients With Selected Advanced Solid Tumours | Not yet recruiting | AUS | 0 |